Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1513 • ACR Convergence 2024
Assessing Subjective Cognitive Impairment in a Cohort of Canadian Systemic Lupus Erythematosus Patients: Construct Validity of PDQ-20
Omar Marzouk¹, J. Antonio Avina-Zubieta², Mary Fox³, William Shaw⁴, Maggie Ho⁵, Qixuan Li⁵, Catherine Ivory⁶, Paul Fortin⁷, Kathleen Bingham⁵, Stephanie Keeling⁸, Jennifer Reynolds⁹, Derek Haaland¹⁰, Janet Pope¹¹, Lily Lim¹², Patti Katz¹³, Murray Urowitz¹⁴, Laura Patricia Whittall Garcia⁵, Dafna Gladman¹⁵, Behdin Nowrouzi-Kia¹⁶ and Zahi Touma¹⁶, ¹Toronto Western Hospital, Toronto, ²Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ³York University, Toronto, ON, Canada, ⁴University of Connecticut, School of Medicine, Farmington, CT, ⁵University Health Network, Toronto, ON, Canada, ⁶The Ottawa Hospital, Ottawa, ON, Canada, ⁷Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ⁸University of Alberta, Edmonton, AB, Canada, ⁹UBC, North Vancouver, BC, Canada, ¹⁰The Waterside Clinic, Oro Medonte, ON, Canada, ¹¹University of Western Ontario, London, ON, Canada, ¹²University of Manitoba, Winnipeg, MB, Canada, ¹³UCSF, San Rafael, CA, ¹⁴Self employed, Toronto, ON, Canada, ¹⁵University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹⁶University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) has many symptoms, including cognitive impairment (CI), which negatively impacts social role participation and quality of life. CI is highly…
Abstract Number: 1530 • ACR Convergence 2024
Belimumab-Treated Patients with Systemic Lupus Erythematosus Without Prior Immunosuppressant Use Have More Favorable Clinical Outcomes Than Those with Prior Use of an Immunosuppressant
Maral DerSarkissian¹, Yan Chen¹, Brendan Rabideau¹, Theo Man¹, Karen Worley², Bernard Rubin³, Karen Costenbader⁴ and S. Sam Lim⁵, ¹Analysis Group, Los Angeles, CA, ²GSK, Collegeville, PA, ³GSK, Durham, NC, ⁴Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁵Emory University, Atlanta, GA

Background/Purpose: Early diagnosis and treatment of SLE improves prognosis and quality of life.1 Belimumab (BEL), a human immunoglobulin G1λ (IgG1λ) mAb that selectively binds to…
Abstract Number: 1550 • ACR Convergence 2024
CD19 CAR T Cell Therapy Suppresses the Inflammatory Profile of Neutrophils in Systemic Lupus Erythematosus
Panagiotis Garantziotis¹, Kirill Anoshkin¹, Melanie Hagen², Andreas Wirsching², Andreas MAckensen³, Georg Schett⁴ and Ricardo Grieshaber-Bouyer⁵, ¹Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ²Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ³Department of Medicine 5 - Hematology and Oncology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁵Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany
Background/Purpose: Patients with Systemic Lupus Erythematosus (SLE) exhibit increased formation of Neutrophil Extracellular Traps and production of proinflammatory cytokines, which can perpetuate autoimmunity. Furthermore, NETs…
Abstract Number: 1701 • ACR Convergence 2024
STING Pathway Activity in SLE Patient Serum Correlates with NFkB Activation, Autoantibody Levels, and a Unique Cytokine Profile That Drives Disease Activity
Hyun Hee Kim¹, Haochen Jiang², Tatiana Ort³, Gary Sims³ and Richard Hanna⁴, ¹AstraZeneca, Gaithersburg, MD, ²University of Nebraska, Omaha, NE, ³Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁴AstraZeneca, Dickerson, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous systemic autoimmune disease which is associated with innate immune activation, type I IFN, inflammasome and NFkB-related cytokines.…
Abstract Number: 1783 • ACR Convergence 2024
Deciphering the Roles of Mitochondrial-Related Genes and Ferroptosis in Systemic Lupus Erythematosus: Integrated Analysis for Diagnostic Biomarker Identification and Therapeutic Insights
Yunfeng Dai and Zhihan Chen, Fujian Medical University, Fuzhou City, Fujian, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous clinical manifestations. Understanding the molecular mechanisms of SLE is crucial for developing effective…
Abstract Number: 1801 • ACR Convergence 2024
Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus
Tania Rowley¹, Adnan R. Khan¹, Laura McLaughlin¹, Hannah Cherry¹, Farnaz Fallah-Arani¹, Yiannis Ioannou¹, Debasish Pyne² and Anthony Shock¹, ¹UCB Pharma, Slough, United Kingdom, ²Barts Health NHS Trust, London, United Kingdom
Background/Purpose: The pivotal role of CD40-CD40L interactions in systemic lupus erythematosus (SLE) pathogenesis stems from the orchestration of a range of immune and inflammatory responses…
Abstract Number: 1909 • ACR Convergence 2024
Racial Disparities in Ocular Complications of Systemic Rheumatic Diseases: A Retrospective Cross-Sectional Study
Insa Mannstadt¹, Yiyuan Wu² and Bella Mehta³, ¹Columbia University VP&S, New York, NY, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: While systemic rheumatic diseases, including Sjogren's syndrome, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and spondyloarthropathies, are known to have severe ophthalmologic manifestations, there…
Abstract Number: 2184 • ACR Convergence 2024
Loss to Follow up After Transfer from Pediatric to Adult Care in Patients with JIA or jSLE
Simran Heera¹, Matthew Sholdice², Tania Cellucci³, Stephanie Garner⁴, Liane Heale⁵, Mark Matsos⁶, KAREN BEATTIE⁷ and Michelle Batthish³, ¹McMaster University, Mississauga, ON, Canada, ²McMaster University, London, ON, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵McMaster University, Oakville, ON, Canada, ⁶McMaster Lupus Clinic, Division of Rheumatology, Department of Medicine, McMaster University, Hamilton, ON, Canada, ⁷McMaster University, Hamilton, ON, Canada
Background/Purpose: In Canada, adolescents with JIA and jSLE transfer from pediatric to adult care around age 18. This vulnerable transition period is associated with an…
Abstract Number: 2385 • ACR Convergence 2024
Increased Type I Interferon Inducible Genes Expression in the Peripheral Blood of Patients Presenting Cutaneous Lupus Erythematosus Manifestations
Anastasia- Bilio Chronopoulou¹, Maria Gerochristou², Sylvia Raftopoulou³, Alexander Stratigos⁴ and Clio Mavragani⁵, ¹National and Kapodistrian University of Athens, Athens, Greece, ²Andreas Syggros Hospital, National and Kapodistrian University of Athens, Athens, Greece, ³Molecular and Applied Physiology Unit, Department of Physiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece, ⁴1st Department of Dermatology-Venereology, Faculty of Medicine, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Athens, Greece, ⁵Department of Physiology and Pathophysiology, School of Medicine, National and Kapodistrian University of Athens., Athens, Greece
Background/Purpose: Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disease characterized by a spectrum of cutaneous manifestations resulting from immune dysregulation and inflammation. While…
Abstract Number: 2404 • ACR Convergence 2024
Nailfold Dermoscopy: A Valuable Tool for Differentiating Dermatomyositis from Systemic Lupus Erythematosus
Caroline Stone¹, Daniella Faden¹, Lillian Xie¹, Lais Lopes Almeida Gomes¹, Joshua Dan¹, Cristina Ricco¹, Ahmed Eldaboush¹ and Victoria Werth², ¹University of Pennsylvania, philadelphia, PA, ²University of Pennsylvania, Wynnewood, PA
Background/Purpose: Dermatoscopes are emerging as efficient, valuable alternatives to capillaroscopy for evaluating rheumatologic conditions. Second to systemic sclerosis, nailfold capillaroscopy abnormalities are most consistently reported…
Abstract Number: 2421 • ACR Convergence 2024
Trends in Glucocorticoid Use in Systemic Lupus Erythematosus in a Population-Based Inception Cohort from 1976 to 2018: The Lupus Midwest Network
Mariana Gonzalez-Trevino¹, Jaime Flores Gouyonnet¹, Qiping Xu², Cassondra Hulshizer³, Jose Meade-Aguilar⁴, Erika Navarro-Mendoza¹, Mario Bautista-Vargas⁵, Gabriel Figueroa-Parra⁶, Alain Sanchez-Rodriguez⁷, Maria Cuellar-Gutierrez¹, Andrew C. Hanson⁸, Cynthia Crowson¹ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Health System - Mankato, Mankato, MN, ³Mayo Clinic, Utica, MN, ⁴Boston University/Boston Medical Center, Boston, MA, ⁵Mayo Clinic, Rochester, Minnesota, USA., Rochester, MN, ⁶Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁷Mayo Clinic College of Medicine and Science, Rochester, MN, ⁸Mayo Clinic, Rochester
Background/Purpose: We examined the patterns of glucocorticoid (GC) use and the temporal trends of GC initiation, discontinuation, and reduction over four decades in a population-based…
Abstract Number: 2438 • ACR Convergence 2024
Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus
Vasileios Kyttaris¹, Gelareh Atefi², Dan Persons³, Dana Withrow³ and Mawuena Binka⁴, ¹BIDMC, Boston, MA, ²AstraZeneca, Media, PA, ³Trio Health, Louisville, CO, USA, Louisville, ⁴BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE
Background/Purpose: Oral corticosteroids (OCS) are a mainstay in the clinical management of systemic lupus erythematosus (SLE). However, prolonged use may result in systemic side effects.1…
Abstract Number: 2601 • ACR Convergence 2024
Platelets Specifically Interact with Remigrating Neutrophils and Promote Immunogenic Cellular Death in Systemic Lupus
Marie nansion¹, Eloi Schmauch², Pierre Vacher³, Jean Sibilia⁴, Nathan Broussaudier¹, Adeline Bruchon¹, Pierre Grenot¹, Anne-Sophie Korganow⁵, Thierry Martin⁵, Sophie Caillard⁶, Anna Duval⁶, Jacques-Eric Gottenberg⁷, Raphaël Carapito¹, Séiamak Bahram¹, Patrick Blanco⁸ and Marc Scherlinger⁹, ¹UMR_INSERM 1109, Strasbourg, France, ²Broad Institute of MIT and Harvard, Cambridge, MA, USA., Boston, MA, ³Inserm U1045, Bordeaux, France, ⁴Strasbourg University Hospital, National reference center for autoimmune disease, Rheumatology, Strasbourg, France, ⁵Strasbourg University Hospital, National reference center for autoimmune disease, Clinical Immunology, Strasbourg, France, ⁶Nephrology department, HUS, Strasbourg, France, ⁷Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁸UMR_CNRS 5164 Immunoconcept, BORDEAUX CEDEX, France, ⁹Strasbourg University Hospital; INSERM 1109, Strasbourg, France
Background/Purpose: In SLE, platelet activation (express P-selectin+) follows the disease activity, which plays a role in thrombosis as well as in inflammation (1). Neutrophils express high levels of PSGL-1,…
Abstract Number: 2681 • ACR Convergence 2024
Association of Social Determinants of Health with Systemic Lupus Erythematosus in the United States: Nationally Representative Estimates for 2017-2021
Ami Vyas, Steven Cohen and Christine Eisenhower, University of Rhode Island, Kingston, RI
Background/Purpose: Careful assessment of individuals’ social determinants of health (SDOH) that affect systemic lupus erythematosus (SLE) is crucial, as such evidence will improve care and…
Abstract Number: 0088 • ACR Convergence 2024
Profound B Cell Depletion and Repopulation with Predominantly Naïve B Cells in Non-Human Primates Achieved Through a Novel In Vivo CD8-Targeted Lipid Nanoparticle mRNA CAR
Aric Frantz¹, Romina Riener¹, Annabel Wang¹, Yanjie Bao¹, Yan Zhang¹, Daiki Matsuda¹, John Li¹, David Chu¹, Theresa Hunter¹, Qian Chen Yong¹, Michelle Nguyen¹, Stuart Sievers¹, Duy Nguyen¹, Scott Roberts¹, Diana Galvan¹, Jerel Boyd Vega¹, Matthew Butcher¹, Stanley Zhang¹, Stephen Flynn¹, Yi Kuo¹, Steven Tanis¹, John Scholler², Gregor Adams¹, Michael Rosenzweig¹, Priya Karmali¹, Adrian Bot¹, Carl June² and Haig Aghajanian¹, ¹Capstan Therapeutics, San Diego, CA, ²University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

Background/Purpose: Ex vivo chimeric antigen receptor (CAR) T cell therapies have revolutionized cancer treatment and are demonstrating durable clinical efficacy in various autoimmune disease indications.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.